thanks danhoff - appreciate the response. Obviously, I got it the wrong way around because from your post it sounds like AT1 are the product developers and its licensed to "partners" like Accessbio and Lumos. Sounds more compelling. Pity about the revenue target but if the product is any good that's just a short term glitch. Depends on maturity and number of competitors tho. I'll take your advice and do some reading - thanks
AT1 Price at posting:
18.5¢ Sentiment: None Disclosure: Not Held
